BioSkryb Genomics has announced two major strategic partnerships aimed at advancing single-cell multi-omics technology and making it more accessible to researchers and clinicians worldwide.
Partnership with 1Cell.Ai to Enhance Cancer Research and Therapy Development
BioSkryb Genomics and 1Cell.Ai have formed a strategic alliance to co-develop and commercialize next-generation single-cell multi-omic solutions. This collaboration merges BioSkryb's single-cell amplification and multi-omics chemistry with 1Cell.Ai's OncoIncytes platform, creating a powerful integrated solution for analyzing rare cell populations.
The partnership specifically targets circulating tumor cells (CTCs), which can now be isolated at a ratio of 1 in a billion. Researchers will be able to characterize DNA, RNA, and protein targets from individual single cells with unprecedented precision, potentially accelerating the development of advanced therapies, including antibody-drug conjugates (ADCs).
"This collaboration represents a powerful synergy of visionary science and cutting-edge technologies," said Dr. James Rothman, Nobel Laureate and Board Member at 1Cell.Ai. "By integrating BioSkryb's single-cell multi-omics chemistry with 1Cell.Ai's capabilities in single cell isolation and multi-omic profiling, we are opening new frontiers in understanding cellular behavior and disease mechanisms at an unprecedented level of clarity."
Samples will be analyzed at both 1Cell.Ai's CLIA laboratory in Foster City, California, and BioSkryb's services laboratory in Durham, North Carolina, providing researchers with comprehensive analytical capabilities.
Suresh Pisharody, CEO of BioSkryb Genomics, emphasized the significance of this partnership: "This partnership with 1Cell.Ai marks a significant advancement in single cell research. By combining BioSkryb's innovative single cell amplification and multi-omics chemistry—which characterizes DNA, RNA, and surface level proteins in a unified workflow—with 1Cell.Ai's breakthrough CTC isolation, multi-omic profiling, and AI-powered analytics, we are providing researchers and clinicians with unprecedented tools to precisely understand disease at the molecular level."
High-Throughput Workflow Development with Tecan Group
In a separate but complementary partnership, BioSkryb Genomics has collaborated with Tecan Group to introduce a high-throughput single-cell workflow. This integration combines BioSkryb's 384-well format of the ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit with Tecan's Uno Single Cell Dispenser.
The new workflow enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing the growing demand for scalable, multi-omics approaches in single-cell research. A key advantage of this system is the reduced reliance on time-consuming cell sorting techniques such as fluorescence-activated cell sorting (FACS), offering a more streamlined approach to comprehensive genomic and transcriptomic profiling.
"This workflow brings next-generation single-cell multi-omics within reach of every lab," said Pisharody. "By reducing the need for complex cell sorting methods like FACS and streamlining the entire multi-omic analysis process, researchers can obtain deep genomic and transcriptomic insights with minimal hands-on time."
The fully integrated workflow simplifies cell isolation, reduces manual handling, and delivers high-quality genomic and transcriptomic sequencing-ready libraries in under ten hours—a significant improvement in throughput and efficiency for single-cell studies.
Mukta Acharya, Head of Tecan's Life Sciences business division, added: "Pairing BioSkryb's ResolveOME chemistry with the Uno Single Cell Dispenser allows researchers to efficiently scale their single-cell studies while maintaining high data quality and reproducibility. Uno's precision dispensing capabilities and broad compatibility also make it an ideal addition to other single-cell workflows, providing flexibility as research needs evolve."
Technology Background and Implications
BioSkryb Genomics has developed patented Primary Template Amplification (PTA) technology that forms the foundation of its products—ResolveDNA®, ResolveOME®, and BaseJumper® bioinformatics solution. These technologies enable the characterization of whole genomes, transcriptomes, and surface proteins of individual cells.
The company's partnership with 1Cell.Ai addresses critical challenges in oncology research, particularly the need for accurate single-cell analysis in developing antibody-drug conjugates. The integrated solution has the potential to shorten drug development timelines and enhance therapeutic precision.
Similarly, the collaboration with Tecan Group focuses on automation, scalability, and ease of use, removing barriers to high-throughput single-cell research. This empowers researchers to accelerate discoveries in cancer research, drug development, and precision medicine.
Market Impact and Future Directions
These strategic partnerships position BioSkryb Genomics at the forefront of the rapidly evolving single-cell analysis market. By making advanced multi-omics technologies more accessible and efficient, these collaborations could significantly accelerate research in oncology, immunology, and other fields where understanding cellular heterogeneity is crucial.
The ability to analyze rare cell populations with high precision and at scale opens new possibilities for early cancer detection, monitoring disease progression, and developing targeted therapies. As these technologies become more widely adopted, they may fundamentally change how researchers approach complex biological questions and how clinicians diagnose and treat diseases.
Mohan Uttarwar, CEO of 1Cell.Ai, summarized the potential impact: "Together, we will deliver transformative solutions that empower researchers and clinicians to tackle the most pressing challenges in biology, medicine, and drug discovery."
